MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
electroCore Balance Sheet 2011-2026 | ECOR
Annual Balance Sheet electroCore
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-53 K | 436 K | -9.7 M | -17 M | -33.9 M | -2.31 M | -11.5 M | -7.6 M | -13.2 M | 3.25 M | - | - | - | - | - |
Long Term Debt |
6.61 M | 3.78 M | 537 K | 625 K | 700 K | 1.4 M | - | - | - | 3.67 M | - | - | - | - | - |
Long Term Debt Current |
375 K | 361 K | 89 K | 74 K | 61 K | 535 K | 486 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 1.42 M | 246 K | 123 M | 57.5 M | - | - | - | - | - |
Total Current Liabilities |
11.3 M | 9.15 M | 8.12 M | 7.04 M | 5.48 M | 5.89 M | 9.14 M | 7.07 M | - | - | - | - | - | - | - |
Total Liabilities |
20.4 M | 12.9 M | 8.66 M | 7.67 M | 6.18 M | 7.87 M | 10.6 M | 7.32 M | 129 M | 61.7 M | - | - | - | - | - |
Retained Earnings |
-191 M | -177 M | -165 M | -146 M | -124 M | - | -83.5 M | -38.3 M | -153 M | -101 M | - | - | - | - | - |
Total Assets |
18.7 M | 20.5 M | 16.1 M | 24.8 M | 42.8 M | 31.5 M | 35.5 M | 73.5 M | 39.2 M | 622 K | - | - | - | - | - |
Cash and Cash Equivalents |
7.04 M | 3.7 M | 10.3 M | 17.7 M | 34.7 M | 4.24 M | 13.6 M | 7.6 M | 13.2 M | - | - | - | - | - | - |
Book Value |
-1.71 M | 7.54 M | 7.44 M | 17.1 M | 36.6 M | 23.6 M | 24.9 M | 66.2 M | -89.5 M | -61.1 M | - | - | - | - | - |
Total Shareholders Equity |
-1.71 M | 7.54 M | 7.44 M | 17.1 M | 36.6 M | 23.6 M | 24.3 M | 65.6 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet electroCore
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
6.53 M | 3.83 M | 3.82 M | 3.78 M | 3.68 M | 3.63 M | 1.57 M | 537 K | 560 K | 583 K | 605 K | 625 K | 645 K | - | 682 K | 700 K | 716 K | 923 K | 874 K | 1.1 M | 885 K | 885 K | 885 K | 1.42 M | 1.42 M | 1.42 M | 1.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
22.5 M | 13.4 M | 11.7 M | 12.9 M | 11.6 M | 10.9 M | 9.39 M | 8.66 M | 9.07 M | 7.16 M | 6.45 M | 7.67 M | 7.29 M | - | 5.36 M | 6.18 M | 6.45 M | 6.68 M | 7.08 M | 7.87 M | 7.87 M | 7.87 M | 7.87 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 7.32 M | 7.32 M | 7.32 M | 7.32 M | 6.43 M | 6.43 M | 6.43 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-188 M | -185 M | -181 M | -177 M | -174 M | -171 M | -169 M | -165 M | -161 M | -157 M | -152 M | -146 M | -141 M | - | -130 M | -124 M | -119 M | -115 M | -112 M | -107 M | -107 M | -107 M | -107 M | -83.5 M | -83.5 M | -83.5 M | -83.5 M | -38.3 M | -38.3 M | -38.3 M | -38.3 M | -153 M | -153 M | -153 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
21.4 M | 14.6 M | 16 M | 20.5 M | 21 M | 22.4 M | 13.9 M | 16.1 M | 20.1 M | 14.2 M | 18.3 M | 24.8 M | 29.5 M | - | 37.2 M | 42.8 M | 47.6 M | 31.3 M | 33.8 M | 31.5 M | 31.5 M | 31.5 M | 31.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 73.5 M | 73.5 M | 73.5 M | 73.5 M | 39.2 M | 39.2 M | 39.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
7.86 M | 3.37 M | 3.78 M | 3.45 M | 4.93 M | 10.3 M | 7.85 M | 10.3 M | 13.5 M | 8.44 M | 11.9 M | 17.7 M | 21.6 M | 26.3 M | 29.9 M | 34.7 M | 38 M | 14.7 M | 9.06 M | 4.24 M | 4.24 M | 4.24 M | 4.24 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 13.2 M | 13.2 M | 13.2 M | - | 416 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-1.07 M | 1.11 M | 4.36 M | 7.54 M | 9.46 M | 11.5 M | 4.5 M | 7.44 M | 11 M | 7.06 M | 11.8 M | 17.1 M | 22.2 M | - | 31.8 M | 36.6 M | 41.1 M | 24.6 M | 26.7 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 66.2 M | 66.2 M | 66.2 M | 66.2 M | 32.8 M | 32.8 M | 32.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-1.07 M | 1.11 M | 4.36 M | 7.54 M | 9.46 M | 11.5 M | 4.5 M | 7.44 M | 11 M | 7.06 M | 11.8 M | 17.1 M | 22.2 M | 27.1 M | 31.8 M | 36.6 M | 41.1 M | 24.6 M | 26.7 M | 23 M | 23 M | 23 M | 23 M | 24.3 M | 24.3 M | 24.3 M | 24.3 M | 65.6 M | 65.6 M | 65.6 M | 65.6 M | -90.1 M | -90.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of electroCore, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
$ 75.8 | -0.08 % | $ 40.4 B |  Schweiz |
 |
Ekso Bionics Holdings
EKSO
|
$ 10.99 | 1.48 % | $ 26.7 M | USA |
 |
The Cooper Companies
COO
|
$ 64.42 | -0.82 % | $ 12.8 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 122.35 | 0.73 % | $ 3.92 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.96 | -0.75 % | $ 183 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 59.93 | 0.52 % | $ 3.02 B | USA |
 |
ICU Medical
ICUI
|
$ 124.82 | 0.22 % | $ 3.08 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 26.8 | -0.89 % | $ 4.5 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.2 | 0.92 % | $ 101 M |  Israel |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 482.22 | 0.71 % | $ 172 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 121.48 | 0.5 % | $ 5.88 B | USA |
 |
Masimo Corporation
MASI
|
$ 178.63 | -0.04 % | $ 9.52 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.32 | -1.27 % | $ 26.3 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 10.34 | 0.68 % | $ 214 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 68.58 | -0.04 % | $ 4.06 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 23.02 | -5.07 % | $ 1.55 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.65 | 0.2 % | $ 19.5 M | USA |
 |
Pro-Dex
PDEX
|
$ 52.1 | 2.24 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 113.45 | 0.49 % | $ 2.57 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 25.67 | 3.34 % | $ 1.27 B | USA |
 |
STERIS plc
STE
|
$ 221.8 | -0.77 % | $ 21.9 B | USA |
 |
BioLife Solutions
BLFS
|
$ 21.38 | -1.57 % | $ 985 M | USA |
 |
Stereotaxis
STXS
|
$ 1.93 | -1.53 % | $ 176 M | USA |
 |
Baxter International
BAX
|
$ 18.16 | -1.39 % | $ 9.32 B | USA |
 |
ResMed
RMD
|
$ 219.85 | 0.15 % | $ 32.1 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 136.56 | -0.07 % | $ 6.09 B | USA |
 |
AtriCure
ATRC
|
$ 29.28 | 3.79 % | $ 1.4 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 6.86 | 1.18 % | $ 305 M | USA |
 |
Utah Medical Products
UTMD
|
$ 67.17 | -1.03 % | $ 218 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 306.16 | -1.14 % | $ 22.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.91 | 0.08 % | $ 2.37 B | USA |
 |
AngioDynamics
ANGO
|
$ 11.1 | -0.89 % | $ 453 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 152.14 | -1.74 % | $ 43.8 B | USA |
 |
Nephros
NEPH
|
$ 2.87 | 1.06 % | $ 29.8 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.0 | -1.64 % | $ 220 M | USA |
 |
Repligen Corporation
RGEN
|
$ 117.6 | 3.1 % | $ 6.55 M | USA |